JJP Biologics expects JJP-1008 to enter clinical studies still this year in 2026 as the second clinical molecule.
Public source
Publisher name
Public post
SMART targeting of HVEM 💡 💡 💡 🪿 🪿 Exciting advances in cancer immunotherapy are highlighting the potential of targeting the HVEM pathway. By blocking HVEM interacti…
Company
JJP Biologics
Next generation of novel biologics around companion diagnostics. Led by industry experts & backed by the Starak family.
- Industry
- Biotechnology
- Location
- Warsaw, PL
- Company size
- 51–200 employees
About JJP Biologics
JJP Biologics is an innovative clinical-stage Polish biotechnology company developing novel biological therapies around established companion diagnostics. Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.
See moreLatest activity
Latest activity from JJP Biologics
6 signals
Research & Knowledge
JJP Biologics published evidence in a current publication showing that JJP-1008 blocks HVEM interactions with BTLA and CD160 while facilitating interaction with LIGHT.
Presence & Recognition
JJP Biologics met Joanna Cygan and Beata Durzyńska from Rezon Bio during the Nordic Life Science Days to discuss European CDMO offerings.
Research & Knowledge
JJP Biologics published a study showing that immunosuppressive signaling of HVEM through BTLA and CD160 is the greatest disadvantage of high HVEM expressing patients.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
ViroCell Biologics
ViroCell Biologics announced the initiation of a second clinical trial at UCL in collaboration with Professor John Anderson using a lentiviral vector from the same initial GMP batch produced in 2024.
Legal & Regulatory
Anticancer Bioscience
Anticancer Bioscience received regulatory clearance for the Investigational New Drug (IND) application for JMBI-001 in China, enabling the program to advance toward a first-in-human Phase 1 clinical study.
Legal & Regulatory
Direct Biologics
Direct Biologics expanded its ongoing Phase III trial beyond COVID-19-associated ARDS to include classic ARDS in 2023 following FDA approval.
Legal & Regulatory
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. received FDA clearance of its IND application for Bria-PROS+â„¢, initiating a Phase 1/2a clinical trial.
Legal & Regulatory
NanoMosaic Inc.